Royal National Orthopaedic Hospital NHS Trust

The RNOH will remain the UK’s leading orthopaedic hospital, further enhancing its international profile for outstanding patient care, research and education

Professor Adrienne M Flanagan

Professor Adrienne M Flanagan

Prof Flanagan, joint medical director, honory consultant histopathologist
Professor Adrienne M Flanagan MB, FRCPath, Ph.D.
Position: 
Consultant Histopathologist, Clinical lead
Email: 
a.flanagan@ucl.ac.uk
Telephone: 
+44 (0)20 8909 5354
Fax: 
+44 (0)20 8954 5908
Specialties: 
Histopathology
Specialist clinical interests: 

Cell and molecular pathology of bone and soft tissue tumours and non-neoplastic musculoskeletal disorders

Research interests: 

Cell biology and genetics of sarcomaCell biology and genetics of sarcoma.
Discovering new diagnostic signatures for sarcoma.
Identifying markers to predict clinical outcome for sarcoma.

Professional profile: 

Consultant Pathologist at the Royal National Orthopaedic Hospital
Honorary consultant, Nuffield Orthopaedic Centre, Oxford
Professor of Musculoskeletal Pathology, UCL
Lead scientist of the cell and genetics of sarcoma team at UCL Cancer Institute
Corporate License Holder of the Human Tissue Authourity license, UCL
Biomedical Research Centre (UCLH/UCL), Cancer Programme Deputy Director
Designated Individual of Human Tissue Authourity licence (research), RNOH
Supervised 12 PhD students, including three currently
Generated ~£1.5M for research over the last five years
Published more than 130 peer-reviewed manuscripts

Education and training: 

FRCPath Part 2 Course (bi-annual) East of England Deanery. Bone and soft tissue disease.
London Deanery Thames Region: ST1 bone and soft tissue pathology. Annual.
London Deanery: SpR bone and soft tissue pathology (every two years).
UCL Cancer Institute MSc: Biomarkers in cancer. Annual.
University representative of the London Deanery specialist training committee for histopathologists.

Memberships: 
UCL Cancer Institute, executive committee member
Clinical lead, International Cancer Genome Consortium Bone Project
Pathological Society of Great Britain and Ireland, committee member
International Skeletal Society, Member-At-Large of the executive committee
Jean Shanks Foundation, trustee
Chordoma Foundation, Scientific Advisory Board
SCAT (Skeletal Cancer Action Trust), trustee/Board member
Royal College of Pathologists, National Quality Assurance Advisory Panel – Pathological Society representative
Editorial Board, Journal of Pathology
Editorial Board, The Open Pathology Journal www.benthamscience.org/open/topatj
Previous responsibilities:
Designated Individual of Human Tissue Authourity licence (research), UCL (2009-2012)
Medical Director, RNOH (2009 – 2012)
Cancer Research UK Stratified Medicine, scientific advisory board member (2010-2011)
Chair of the Medical Staff Committee RNOH (2007-2009)
Co-Chair of the Medical Staff Committee RNOH (2005-2007)
Pathological Society of Great Britain and Ireland (2007-2009)
Recent and Important Publications: 
  1. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, M Amary F, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013) Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genet. 45:1479-1482
  2. Patrick S Tarpey PS, Behjati S, Susanna Cooke S, Van Loo P, Wedge DC, Pillay N, John Marshall J, O’Meara S, Davies H, Nik-Zainal S, Beare D, Butler A, Gamble J, Hardy C, Hinton C, Jia MM, Jayakumar A, Jones, D, Latimer C, Maddison M, Martin S, McLaren S, Menzies A, Mudie L, Raine K, Teague JW, Tubio J, Halai D, Tirabosco R, Amary F, Campbell PJ, Stratton MR, Flanagan AM, Futreal AM (2013) Frequent   mutation   of   the   major  cartilage   collagen   gene, COL2A1, in chondrosarcoma. Nature Genet.  45:923-926
  3. Guilhamon P, Eskandarpour M , Halai D, Wilson GA, Feber A, Teschendorff AE, Gomez V, Hergovich A, Tirabosco R, Amary MF, Baumhoer D, Jundt G, Ross MT, Flanagan AM, Beck S (2013) Meta-analysis of IDH-mutant cancers identifies EBF1 as a novel interaction partner for TET2. Nature Comm. 4:2166-2175
  4. Savage SA, Mirabello l, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, barkauskas da, Marina n, de toledo sr, petrilli as, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter dj, malats n, kogevinas m, wacholder S, Troisi R, Helman L, Fraumeni JF Jr, Yeager M, Hoover RN, Chanock SJ (2013) Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genet. 45:799-803
  5. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, Aston W, Green CL, Gale RE, Tirabosco R, Futreal A, Campbell P, Presneau N, Flanagan AM (2011) Ollier disease and Maffuci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.  Nature Genet. 43:1262-1265
  6. Pillay N, Plagnol V, Tarpey PS, Lobo S, Presneau N, Szuhai K, Halai D, Berisha F, Cannon SR, Mead S, Kasperavicute D, Palmen J, Talmud P, Kindblom LG, Amary MF, Tirabosco R, Flanagan AM. (2012) A common single nucleotide variant in T is strongly associated with chordoma. Nature Genet.  14:1185-1197
  7. Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, Berisha F, Flicek P, Stemple DL, Stern C, Wardle FC, Flanagan AM. (2012) An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. J Pathol. 228:274-285
  8. Presneau N, Eskandarpour M, Shemais T, Henderson S, Halai D, Tirabosco R, Flanagan AM. Micro-RNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. Brit. J. Cancer 2012 Nov 22. doi: 10.1038/bjc.2012.518
  9. Kashima TG, Halai D, Ye H, Hing SN, Delaney D, Robin Pollock R, O’Donnell P, Tirabosco R, Flanagan AM (2012) Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor and well differentiated liposarcoma. Mod. Pathol. 5:1384-96
  10. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O’Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM  (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.  J. Pathol. 224:334-343.
    Winner of the Jeremy Jass prize for Research Excellence in Pathology - 2011.
  11. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, Aston W, Green CL, Gale RE, Tirabosco R, Futreal A, Campbell P, Presneau N, Flanagan AM (2011) Ollier disease and Maffuci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.  Nature Genet. 43:1262-1265
  12. Damato S, Alorjani M, Bonar F, McCarthy SW, Cannon SR, O’Donnell P, Tirabosco R, Amary MF, Flanagan AM  (2012) IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas.  Histopathology 60:363-365
  13. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27-40
  14. Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirbabosco R, Flanagan AM (2009) Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.  Br. J. Cancer 100:1406-1414
  15. Shalaby AA, Presneau N, Idowu BD, Thompson L, Briggs TR, Tirabosco R, Diss TC, Flanagan AM (2009) Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.  Mod. Pathol. 22:996-1005
  16. Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, Leithner A, Liegl B, Briggs TWR, Bacsi K, Kindblom LG, Athanasou N, Amary MF, Hogendoorn PCW, Tirabosco R, Flanagan AM  (2010) The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.  J. Pathol. 223:336-346
  17. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques T, Kindblom LG, Bruderlein S, Moller P, Leithner A, Liegl B, Amary MF, Athanasou NN, Hogendoorn PCW, Mertens F, Szuhai K, Flanagan AM  (2010) Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study.  J. Pathol. 223:327-335
  18. Vujovic S, Henderson S, Presneau N, Odell E, Jacques T, Tirabosco R, Boshoff C and Flanagan AM  (2006)  Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas.  J. Pathol.  209:157-165
  19. Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di Francesco L, Kalil RK, Athanasou NA, O’Donnell P, McCarthy EF and Flanagan AM (2008) Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am. J. Surg. Pathol. 32:572-580

Previous invited lectures, and teaching courses

  1. June 2012: First European Chordoma Foundation meeting, organised by patients for patients. The pathology of chordoma.
  2. 2012 Oct: International Association of Pathologists, Annual meeting. S. Africa. Molecular genetics of chordoma.
  3. 2012 Oct: International Association of Pathologists, Annual meeting. S. Africa. Hardcastle Syndrome.
  4. 2012 Oct: International Association of Pathologists, Annual meeting. S. Africa. Spindle cell and non-epithelial lesions of the genitourinary tract.
  5. 2012 March: AGIOS Pharmaceuticals, Inc. Boston, USA. IDH1 mutations in cartilaginous tumours.
  6. 2012 March: Durham Academy / high school, N. Carolina, USA: The history of pathology, and developing new treatments for chordoma.  I spoke to the class in which a child in this school died of chordoma. I had met the child and family in 2007. I also used took the opportunity to meet with scientists in Duke University, & GSK pharmaceuticals.
  7. 2012 March: Sarcoma UK Society, Annual meeting: The International Cancer Genome Project.
  8. 2012 March: Sarcoma UK Society, Annual meeting: Introducing new therapies for treatment of sarcoma.
  9. 2011 Sept: European Society of Pathology, Helsinki: Chordoma: molecular insights & potential target identification.
  10. 2011 Apr: Jordanian Society of Pathology, Annual meeting. Benefits of molecular pathology in bone & soft tissue tumours
  11. 2011 Apr: Association for Clinical Cytogenetics, Annual meeting. Durham, Scotland.  The value of molecular pathology in providing a clinical service.
  12. 2011 Mar: Chordoma Foundation meeting. The role of brachyury in chordoma, for researchers.
  13. 2011 Mar: Lecture to patients and families members, with chordoma. Diagnosing and treating chordomas.
  14. 2010 Nov: Childhood Bone Sarcoma Genomics Consortium representing the Wellcome Trust Sanger Institute. Paris meeting.
  15. 2010 Nov: Problematic low grade lesions in bone and soft tissue. RCPath course.
  16. 2010 Jul: 43rd Annual Musculoskeletal Tumour Meeting, Japanese Orthopaedic Association. Molecular genetics of chordoma.
  17. 2010 Jul: 43rd Annual Musculoskeletal Tumour Meeting, Japanese Orthopaedic Association. The pathology of osteoclast-rich tumours.
  18. 2009 Jun: International Cancer Genome Consortium, First meeting at Wellcome Trust Sanger Institute. ‘Bone tumours project – Sequencing 500 bone tumours’.
  19. 2010 May: Problematic high grade lesions in bone and soft tissue. RCPath course.
  20. 2010 Feb: World Association of Societies of Pathology and Laboratory Medicine (WASPaLM). Chandigarh India. Lectures on bone tumour pathology to post graduates/consultants
  21. 2009 Jun: Bone Cancer Research Trust.  Lecture to patients/families with bone tumours. How molecular pathology will provide new therapeutic targets.
  22. 2008 Nov: World Association of Societies of Pathology and Laboratory Medicine (WASPaLM), Anatomical Pathology Update, Penang, Malaysia. Bone and Soft tissue Lectures and Seminars.
  23. 2008 Oct: International Skeletal Society, Delhi India. Osteoarthritis – latest facts and fiction.
  24. 2008 Oct: International Academy of Pathologists. Greece. Mimics of malignancy in bone and soft tissue lesions.
  25. 2008 Jun: 14th International Congress of Oral Pathology and Medicine. San Francisco. Molecular genetic events in fibro-osseous and osteoclast-rich lesions of the jaw. Lecture and Seminar.
     

 

Previous responsibilities

Prof Falnagan is a guest Faculty Member at the The 5th Annual Sacro Pelvic Tumor Study Group Conference held by the Massachusetts General Hospital (Boston, MA), the Mayo Clinic (Rochester, MN) and the Memorial Sloan-Kettering Cancer Center (New York, NY ). The conference was was founded in 2008 as a collaboration with Massachusetts General Hospital (Boston, MA ), the Mayo Clinic (Rochester, MN) and the Memorial Sloan-Kettering Cancer Center (New York, NY).

2013  - Elected a Meeting Secretary of the Pathological Society of Great Britain and Ireland (officer of the society)

2013  - Appointed Head of Pathology (research)  at UCL in February

2013  - Corporate License Holder of the Human Tissue Authourity license, UCL - which now includes biobank at RNOH

2012  - Biomedical Research Centre (UCLH/UCL), Cancer Programme Deputy Director

2013  - Sarcoma UK Research Advisory Committee

2012  - Trustee of the Jean Shanks Foundation

Designated Individual of Human Tissue Authourity licence (research), UCL (2009-2012)
Medical Director, RNOH (2009 – 2012)
Cancer Research UK Stratified Medicine, scientific advisory board member (2010-2011)
Chair of the Medical Staff Committee RNOH (2007-2009)
Co-Chair of the Medical Staff Committee RNOH (2005-2007)
Pathological Society of Great Britain and Ireland (2007-2009)
 

How helpful did you find this page?
Not helpful
Very helpful *
Required fields *
Royal National Orthopaedic Hospital Trust